Abstract
The immune microenvironment is considered a major obstacle to generating an effective antitumor immune response. Checkpoint inhibitors manipulate the co-stimulatory response between antigen-presenting cells and immune cells-or between the tumor and immune cells-to elicit an antitumor immune response that would have otherwise been suppressed. Checkpoint inhibitors have shown great promise in the clinics, and some inhibitors such as anti-CTLA-4 antibodies and anti-PD-1 antibodies have gained FDA approval for certain tumors. Here we will discuss the current state of checkpoint inhibitors, biomarker strategies, and management of associated toxicities in glioblastoma.
Original language | English (US) |
---|---|
Pages (from-to) | vii26-vii31 |
Journal | Neuro-oncology |
Volume | 17 |
DOIs | |
State | Published - Nov 1 2015 |
Keywords
- biomarker
- checkpoint blockade
- clinical trial
- glioblastoma
- immunotherapy
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
- Cancer Research